Oral Edaravone Appears Safe in Patients, Interim Trial Data Show

Oral Edaravone Appears Safe in Patients, Interim Trial Data Show

314064

Oral Edaravone Appears Safe in Patients, Interim Trial Data Show

An oral suspension formulation of edaravone (MT-1186) is safe and well-tolerated in adults with amyotrophic lateral sclerosis (ALS), according to interim, six-month data from a Phase 3 clinical trial. In addition, exploratory efficacy results suggest that edaravone’s experimental oral formulation may slow patients’ functional decline to a similar level to its approved, into-the-vein formulation, Radicava. These findings, supporting the safety and potential efficacy of oral edaravone, were presented in a poster at the 32nd International Symposium…

You must be logged in to read/download the full post.